CLN5 Disease Clinical Trials

Find CLN5 Disease Clinical Trials Near You

A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Genetic
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a registrational, first-in-human, open-label, dose escalation and expansion study evaluating the safety, tolerability and effectiveness of TTX-381, administered by injection under the retina, for the treatment of eye problems caused by CLN2 (Batten disease). The study includes dose escalation and expansion groups evaluating treatment in one or both eyes. Participants are followed for 5 years after treatment to assess safety and clinical outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 7
Healthy Volunteers: f
View:

∙ Participants must meet all of the following criteria:

• Biallelic CLN2 mutations.

• Decreased leukocyte TPP1 activity.

• Clinical signs or symptoms consistent with CLN2 disease, such as developmental delay or decline, seizures, vision loss, or an older sibling with confirmed CLN2 diagnosis.

• Currently receiving biweekly ICV ERT treatment with cerliponase alfa.

• Age ≥24 month and ≤84 months at screening

• In the phase of accelerated decline in CRT with the following baseline retinal criteria confirmed by the central reading center:

‣ CRT ≤210 μm and

⁃ CRT ≥140 μm in both eyes and

• Is willing and able to comply with the protocol and 5-year visit schedule.

∙ Written informed consent must be provided by the participants parent(s) or legally authorized representative(s)

Locations
Other Locations
Germany
University Medical Center Hamburg-Eppendorf (UKE)- Childrens Hospital
RECRUITING
Hamburg
United Kingdom
Greater Ormond Street Hospital
RECRUITING
London
Contact Information
Primary
Tern Therapeutics Patient Advocacy
patientadvocacy@terntx.com
202-644-8488
Time Frame
Start Date: 2023-05-17
Estimated Completion Date: 2031-12
Participants
Target number of participants: 26
Treatments
Experimental: Cohort 1: Dose Level 1
2×10\^10 GC/eye
Experimental: Cohort 2: Dose Level 2
6×10\^10 GC/eye
Experimental: Cohort 3: Expansion Cohort
2×10\^10 GC/eye
Experimental: Cohort 4: Bilateral Administration
2×10\^10 GC/eye administered once per eye
Sponsors
Leads: Tern Therapeutics, LLC

This content was sourced from clinicaltrials.gov